$ALLR News
Last published 1w ago
- 1w agoALLRAllarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring RevenueGlobeNewswire- Agreement complements revenue from standard gene expression and DRP® services - Development and validation services will support a European biotechnology company’s precision oncology predictive device for use in the
- 2w agoALLRALTERITY THERAPEUTICS (ATHE) FIRESIDE CHAT - ALLARITY THERAPEUTICS INCEarnings Call TranscriptsAll right. Welcome back, everyone, tuning in to today's Biotech Catalyst Conference here at Craig Hollam. My name is Adam Vogel. I'm a senior biotech analyst here. And today with us, we have from Alterity Therapeutics, C
- 1mo agoALLRAllarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib DevelopmentGlobeNewswireTARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing
- 3mo agoALLRAllarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing CampaignGlobeNewswire- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic into 2042 -
- 4mo agoALLRAllarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA RegistrationGlobeNewswireAllarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory environmentThe FDA requires that biomarker testing to select patients for registration trials must be
- 4mo agoALLRAllarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion DiagnosticGlobeNewswireKey U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the
- 4mo agoALLRAllarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026GlobeNewswirePrincipal Investigator Kathleen N. Moore, M.D., a leading expert in advanced ovarian cancer, will present the poster TARPON SPRINGS, Fla., June 18, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the
- 6mo agoALLRAllarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple CancersGlobeNewswire- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer- Allarity has received a Notice of Allowance for new intellectual property
- 6mo agoALLRAllarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in StockholmGlobeNewswireTARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a
- 6mo agoALLRAllarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing CampaignGlobeNewswirePhase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancerSupports accelerating stenoparib toward FDA approval
- 6mo agoALLRAllarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark OfficeGlobeNewswirePatent expected to be formally granted within three months, subject to standard administrative proceduresPatent would provide exclusivity at least into 2039 for stenoparib when used in concert with the stenoparib DRP
- 6mo agoALLRAllarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian CancerGlobeNewswireNew AACR data highlight stenoparib's potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® companion diagnostic is associated with enhanced overall survival in Ovarian Cancer
- 7mo agoALLRAllarity Therapeutics Reports Full Year 2025 Financial Results and Corporate ProgressGlobeNewswireStrengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling
- 8mo agoALLRAllarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and CommercializationGlobeNewswireExtends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and CommercializationFinancing Structured as
- 8mo agoALLRAllarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet NeedGlobeNewswireStenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for enrollment at 11 VA
- 9mo agoALLRAllarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for EnrollmentGlobeNewswireThis is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S.
- 10mo agoALLRAllarity Therapeutics Issues 2025 End of Year CEO Letter to ShareholdersGlobeNewswireTARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a
- 12mo agoALLRAllarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireReceived FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new
- 1y agoALLRAllarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 MonthsGlobeNewswire- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily - Two patients
- 1y agoALLRAllarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025GlobeNewswireTARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a
- 1y agoALLRAllarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian CancerGlobeNewswireTARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated,
- 1y agoALLRAllarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New PartnershipsGlobeNewswire- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic- Secured new
- 1y agoALLRAllarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform UtilizationGlobeNewswireTARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a
- 1y agoALLRAllarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial OfficerGlobeNewswireTARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated,
- 1y agoALLRAllarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion DiagnosticGlobeNewswireTARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a
- 1y agoALLRAllarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian CancerGlobeNewswireTARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a
- 1y agoALLRAllarity Therapeutics Announces Changes to Board of DirectorsGlobeNewswireTARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated,
- 1y agoALLRAllarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib's Unique, Dual Therapeutic Mechanism of ActionGlobeNewswireTARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated,
- 1y agoALLRAllarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian CancerGlobeNewswireTARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a
- 1y agoALLRAllarity Therapeutics Announces Participation in Pharma Partnering Summit USGlobeNewswireTARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a
- 1y agoALLRAllarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial EnrollmentGlobeNewswire- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months- Initiated utilization of share repurchase program-
- 1y agoALLRAllarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025GlobeNewswireTARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual
- 1y agoALLRAllarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateGlobeNewswireCash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities into 2027Strengthened cash position expected to support the Company through
- 1y agoALLRAllarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its SharesGlobeNewswireBoston (March 24, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt
- 1y agoALLRAllarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic OncologyGlobeNewswireThe Annual Meeting is the foremost educational and scientific event for gynecologic oncologistsStenoparib has shown clinical benefit in heavily pre-treated patients, including those with platinum-resistant and
- 1y agoALLRAllarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange CommissionGlobeNewswireBoston (March 13, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt
- 1y agoALLRAllarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans AdministrationGlobeNewswireTrial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatment Fully funded by the U.S. Veterans' Administration Special Emphasis Panel on Precision
- 1y agoALLRAllarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase ProgramGlobeNewswireBoston (March 3, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway
- 1y agoALLRAllarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer PatientsGlobeNewswirePatient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and the stenoparib-DRP Companion Diagnostic toward FDA approvalTwo patients in the
- 1y agoALLRAllarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian CancerGlobeNewswireBoston (February 6, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt
- 1y agoALLRAllarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SECGlobeNewswireBoston (January 30, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its
- 1y agoALLRAllarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate AdvancementsGlobeNewswireTwo patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical development toward
- 1y agoALLRAllarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational HighlightsGlobeNewswireCash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the
- 2y agoALLRINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Allarity Therapeutics, Inc. ("Allarity" or...
- 2y agoALLRINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options If you suffered losses
- 2y agoALLRAllarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for StenoparibGlobeNewswireEuropean Patent Office to grant a patent for DRP® companion diagnostic for Allarity's stenoparib cancer therapy Patent applications for the Stenoparib DRP® are also pending in the US, Japan, China, Australia,
- 2y agoALLRINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Allarity Therapeutics, Inc. ("Allarity" or...
- 2y agoALLRAllarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementGlobeNewswireBoston (October 10, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on
- 2y agoALLRAllarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor ProgramGlobeNewswireFormer Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company's clinical development programsEli Lilly and Celgene veteran Jose Iglesias, M.D.,
- 2y agoALLRAllarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer TrialGlobeNewswire- Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated Patients Boston (September 16, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage